참고문헌
- Aapro M, Abrahamsson PA, Body JJ, et al (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol, 19, 420-32.
- Aapro MS, Coleman RE (2012). Bone health management in patients with breast cancer: current standards and emerging strategies. Breast, 21, 8-19. https://doi.org/10.1016/j.breast.2011.08.138
- Ariffin OZ, Nor Saleha IT (2011). National Cancer Report 2007, Ministry of Health, Malaysia.
- Bagi CM (2005). Targeting of therapeutic agents to bone to treat metastatic cancer. Advanced Drug Delivery Reviews, 57, 995-1010. https://doi.org/10.1016/j.addr.2004.12.014
- Bernard DS, Farr SL, Fang Z (2011). National estimates of outof-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol, 29, 2821-6. https://doi.org/10.1200/JCO.2010.33.0522
- Bradley C (2006). Feedback on the FDA's February 2006 draft guidance on patient reported outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes, 4, 78. https://doi.org/10.1186/1477-7525-4-78
- Castellano D, Sepulveda JM, Garcia-Escobar I, et al (2011). The role of rank-ligand inhibition in cancer: the story of Denosumab. Oncologist, 16, 136-45. https://doi.org/10.1634/theoncologist.2010-0154
- Cohen DJ, Reynolds MR (2008). Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol, 52, 2119-26. https://doi.org/10.1016/j.jacc.2008.09.018
- Coleman RE (1997). Skeletal complications of malignancy. Cancer, 80, 1588-94. https://doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G
- Coleman RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 27, 165-76. https://doi.org/10.1053/ctrv.2000.0210
- Coleman RE (2004). Bisphosphonates: clinical experience. Oncologist, 9, 14-27.
- Coleman RE (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 12, 6243-9. https://doi.org/10.1158/1078-0432.CCR-06-0931
- Colloca G, Colloca P (2011). Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration - resistant prostate cancer: which instrument we need? Med Oncol, 28, 519-27. https://doi.org/10.1007/s12032-010-9495-2
- DePuy V, Anstrom KJ, Castel LD, et al (2007). Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, 15, 869-76. https://doi.org/10.1007/s00520-006-0203-x
- Dhillon S, Lyseng-Williamson KA (2008). Zoledronic Acid: A review of its use in the management of bone metastases of malignancy. Drugs, 68, 507-34. https://doi.org/10.2165/00003495-200868040-00010
- Felix J, Andreozzi V, Soares M, et al (2011). Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value in Health, 14, 499-505. https://doi.org/10.1016/j.jval.2010.11.014
- Fidler IJ (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Natural Review of Cancer, 3, 453-8. https://doi.org/10.1038/nrc1098
- Fong MK, Hare R, Jarkowski A (2012). A new era for castrate resistant prostate cancer: a treatment review and update. J Oncol Pharm Practice, 18, 343-54. https://doi.org/10.1177/1078155212437599
- Goh P, Harris K, Napolskikh J, et al (2007). New integrative therapies for oncology: multidisciplinary prostate bone metastases clinic: first of its kind in Canada. Current Oncology, 14, 9-12. https://doi.org/10.3747/co.2007.101
- Hagiwara M, Oglesby A, Chung K, Zilber S, Delea TE (2011). The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Commun Oncol, 8, 506-15.
- Hadji P (2011). Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Critical Reviews in Oncology/Hematology, 80, 301-13 https://doi.org/10.1016/j.critrevonc.2011.03.007
- Hadji P, Aapro M, Costa L, Gnant M (2012). Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treatment Reviews, 38, 815-24. https://doi.org/10.1016/j.ctrv.2012.03.002
- Jilani A, Garrett Z, Sutcliffe F, Stevens A (2012). NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours. Lancet Oncol, l3, 1194-5.
- International Agency for Research on Cancer and Cancer Research UK (2012). World cancer factsheet. Cancer Research UK: London.
- Johnson JR, Williams G, Pazdur R (2003). End points and the food and drug administration. J Clin Oncol, 21, 1404-11. https://doi.org/10.1200/JCO.2003.08.072
- Kim A, Fall P, Wang D (2005). Palliative care: optimizing quality of life. J Am Osteopath Assoc, 105, 9-14.
- Konski A (2004). Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis for prostate cancer. Int J Radiat Oncol Biol Phys, 60, 1373-8. https://doi.org/10.1016/j.ijrobp.2004.05.053
- Lage MJ, Barber BL, Harrison DJ, Jun S (2008). The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care, 14, 317-22.
- Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D (2006). Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer, 106, 1875-82. https://doi.org/10.1002/cncr.21824
- Meneses K, Azuero A, Hassey L, McNees P, Pisu M (2012). Does economic burden influence quality of life in breast cancer survivors? Gynecologic Oncol, 124, 437-43. https://doi.org/10.1016/j.ygyno.2011.11.038
- Ministry of Health Malaysia (2010). Malaysian Clinical Practice Guideline of Cancer Pain Management.
- Ministry of Health Malaysia, Ministry of Higher Education Malaysia (2011). Protocol for Systemic Therapy of Cancer. Second edition. Malaysia.
- Ministry of Health Malaysia (2012). MOH Health facts 2012. Health Informatics Centre Planning and Development Division, MOH.
- Mundy GR (1997). Mechanisms of bone metastasis. Cancer, 80, 1546-56 https://doi.org/10.1002/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I
- Namiki M, Akaza H, Lee SE, et al (2010). Prostate cancer working group report. Jpn J Clin Oncol, 40, 70-5 https://doi.org/10.1093/jjco/hyq130
- Ng CH, Pathy NB, Taib NA, et al (2011). Comparison of breast cancer in Indonesia and Malaysia ? a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pac J Cancer Prev, 12, 2943-6.
- Ogce F, Ozkan S (2008). Changes in functional status and physical and psychological symptoms in women receiving chemotherapy for breast cancer. Asian Pac J Cancer Prev, 9, 449-52.
- Osanto S, Van Poppel H (2012). Emerging novel therapies for advanced prostate cancer. Ther Adv Urol, 4, 3-12. https://doi.org/10.1177/1756287211432777
- Osoba D (2011). Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol, 3, 57-71. https://doi.org/10.1177/1758834010395342
- Payne H, Pearcy R (2012). Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective. J Men's Health, 9, 9-16. https://doi.org/10.1016/j.jomh.2011.11.002
- Penson DF, Moul JW, Evans CP, et al (2004). The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol, 171, 2250-4. https://doi.org/10.1097/01.ju.0000127732.63726.4c
- Saad F, Lipton A, Cook R, et al (2007). Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 110, 1860-7. https://doi.org/10.1002/cncr.22991
- Schulman KL, Kohles J (2007). Economic burden of metastatic bone disease in the U.S. Cancer, 109, 2334-42. https://doi.org/10.1002/cncr.22678
- Shahmoradi N, Kandiah M, Loh SP (2010). Quality of life and functional status in patients with advanced cancer admitted to hospice home care in Malaysia: a cross-sectional study. Eur J Cancer Care, 21, 661-6.
- Shih YC, Xu Y, Cormier JN, et al (2009). Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol, 27, 2007-14. https://doi.org/10.1200/JCO.2008.18.3517
- Taib NA, Yip CH, Low WY (2011). Recognising symptoms of breast cancer as a reason for delayed presentation in Asian Women-the psycho-socio-cultural model for breast symptom appraisal: opportunities for intervention. Asian Pac J Cancer Prev, 12, 1601-8.
- Tamura K (2012), Medical oncology in Asia. Chin Clin Oncol, 1, 2.
- Testa MA, Simonson DC (1996). Assessment of quality-of life outcomes. N Engl J Med, 334, 835-40. https://doi.org/10.1056/NEJM199603283341306
- World Health Organisation (2011). Cancer Fact Sheet No 297. The World Health Organisation: Geneva
- Yoo KY (2010). Cancer prevention in the Asia Pacific Region. Asian Pac J Cancer Prev, 11, 839-44
피인용 문헌
- Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications pp.36, 2016, https://doi.org/10.1200/EDBK_159203